DRUG
Plecanatide
Plecanatide tablets QD for 12 weeks
Status
Completed
Phase
Phase 3
Enrollment
1,394
Locations
189
Results
Posted
Publications
5
Study summary
The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.
This is a randomized, 12-week, double-blind, placebo-controlled, study in approximately 1350 adult male and female patients with CIC comparing 2 doses of plecanatide to placebo. The study will be conducted at approximately 180 clinical study sites in the United States (US) and Canada. The primary objective of the study is to evaluate the efficacy and safety of 3.0 and 6.0 mg of plecanatide administered once daily (QD) for 12 weeks in a population of patients with CIC. The study population will include only patients without other causes of constipation or other chronic conditions that could interfere with study assessments. Patients may not take laxatives (with the exception of the study-provided rescue medication, bisacodyl 5mg tablets), or a number of prohibited drugs that are known to cause constipation or diarrhea, during study participation. There are 6 scheduled study visits, including the screening and follow-up visits. The planned duration of participation in this study will be 112 days and up to 155 days, with washout and all visit windows considered.
Interventions
DRUG
Plecanatide tablets QD for 12 weeks
DRUG
Matching placebo tablets QD for 12 weeks
DRUG
Rescue medication
Timeline
First posted
Nov 13, 2013
Study start
Nov 2013
Primary completion
Apr 2015
Study completion
Jun 2015
Results posted
Mar 21, 2019
Registry updated
Dec 26, 2019
Outcomes
Number of Durable Overall CSBM Responders , Mean Replacement Approach
Time frame · 12-week Treatment Period
A durable overall CSBM responder was defined as a weekly CSBM responder for at least 9 of the 12 treatment weeks, included at least 3 of the last 4 weeks. A CSBM weekly responder was defined as a patient who has ≥ 3 Complete Spontaneous Bowel Movements (CSBMs) per week and an increase from baseline of ≥1 CSBM for that week. A CSBM was a bowel movement that occurred in the absence of laxative use within 24 hours and was associated with the feeling of complete evacuation.
Change From Baseline in CSBMs (CSBMS/Week) Over 12-week Treatment Period, Mean Replacement Approach
Time frame · 12-Week Treatment Period
A Complete Spontaneous Bowel Movement (CSBM) was a Bowel Movement (BM) that occurred in the absence of laxative use within 24 hours of the BM and the patient reported a feeling of complete evacuation. A weekly responder had 3 or more CSBMs and an increase of at least one CSBM from baseline in the same week.
Change From Baseline in SBM (SBMs/Week) Over 12-week Treatment Period, Mean Replacement Approach
Time frame · 12-Week Treatment Period
The change from baseline in the number of Spontaneous Bowel Movement (SBM) over the 12-week Treatment Period was assessed. Baseline was the mean number of SBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly SBM totals were derived from the daily diary entries reported during the Treatment Period in the BM and Symptom Diary.
Change From Baseline in Stool Consistency Score Over the 12-week Treatment Period, Mean Replacement Approach
Time frame · 12-Week Treatment Period
The stool consistency of each bowel movement (BM) was assessed by patients using the 7-point Bristol Stool Form Scale \[BSFS\] from 1 to 7. 1. = separate hard lumps like nuts (difficult to pass) 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on its surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges (passed easily) 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces (entirely liquid)
Change From Baseline in Straining Score Over 12-Week Treatment Period, Mean Replacement Approach
Time frame · 12-Week Treatment Period
Baseline was the mean of non-missing straining scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly average straining score was derived from the straining scores reported during the Treatment Period in the Daily Symptom Diary. The severity of straining during bowel movements was assessed on a 5-point Likert scale where 0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.
Eligibility
Inclusion Criteria: * Male or female aged 18-80, inclusive * Meets modified Rome III criteria for functional chronic idiopathic constipation for at least 3 months with symptom onset for at least 6 months * Completed a colonoscopy in accordance with AGA colon cancer screening guidelines (5 years), with no clinically significant findings * Willing to maintain a stable diet during the study Exclusion Criteria: * Loose stool (mushy) or watery (Bristol score 6 or 7) stool in the absence of any laxative or prohibited medicine for \> 25% of BMs during the 3 months prior to screening visit OR during the 14 day pre-treatment assessment * Active peptic ulcer disease, diabetes or hypertension not adequately treated or not stable * History of cathartic colon, laxative, enema abuse, or ischemic colitis * Fecal impaction within 3 months of screening * Patient has had /has any: diseases or conditions associated with constipation (GI or CNS), structural abnormality of the GI tract or gastric bypass surgery, pelvic floor dysfunction, pseudo-obstruction, active infectious gastritis, diverticulitis, anal fissures or any disease or condition that can affect GI motility or defecation or can be associated with abdominal pain * Unexplained and clinically significant "alarm symptoms" including lower GI bleeding, iron-deficiency anemia, weight loss or systemic signs of infection or colitis * Major surgery, stroke or MI within 60 days of screening * Participated in a previous plecanatide clinical trial
Study locations
Canada · United States. Showing up to 24 locations stored in the fast local snapshot.
Synergy Research Site
Birmingham, Alabama, United States
Synergy Research Site
Dothan, Alabama, United States
Synergy Research Site
Gulf Shores, Alabama, United States
Synergy Research Site
Huntsville, Alabama, United States
Synergy Research Site
Mobile, Alabama, United States
Synergy Research Site
Mesa, Arizona, United States
Synergy Research Site
Phoenix, Arizona, United States
Synergy Research Site
Phoenix, Arizona, United States
Synergy Research Site
Tempe, Arizona, United States
Synergy Research Site
Tucson, Arizona, United States
Synergy Research Site
Hot Springs, Arkansas, United States
Synergy Research Site
Little Rock, Arkansas, United States
Synergy Research Site
North Little Rock, Arkansas, United States
Synergy Research Site
Anaheim, California, United States
Synergy Research Site
Anaheim, California, United States
Synergy Research Site
Carlsbad, California, United States
Synergy Research Site
Cerritos, California, United States
Synergy Research Site
Chula Vista, California, United States
Synergy Research Site
El Cajon, California, United States
Synergy Research Site
Encinitas, California, United States
Synergy Research Site
Encino, California, United States
Synergy Research Site
Fountain Valley, California, United States
Synergy Research Site
Fresno, California, United States
Synergy Research Site
Hawaiian Gardens, California, United States
Publications
Related trials
Bausch Health Americas, Inc. · Functional Constipation (FC)
Phase 2
Active, not recruiting
180
2026-07
University of Wisconsin, Madison · Barrett Esophagus · Gastroesophageal Reflux Disease
Phase 1
Completed
43
2026-04
Bausch Health Americas, Inc. · Irritable Bowel Syndrome With Constipation
Phase 2
Completed
218
2025-12
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. · Functional Constipation
Phase 3
Completed
648
2024-07
Bausch Health Americas, Inc. · Irritable Bowel Syndrome
Phase 3
Completed
2,272
2020-08
Bausch Health Americas, Inc. · Chronic Idiopathic Constipation
Phase 2
Completed
84
2020-01
Bausch Health Americas, Inc. · Chronic Idiopathic Constipation
Not applicable
Completed
7
2019-11
Bausch Health Americas, Inc. · Chronic Idiopathic Constipation
Phase 2
Completed
124
2019-10
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.